We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Alterations Associated with Sporadic Congenital Hydrocephalus

By LabMedica International staff writers
Posted on 02 Nov 2020
Image: A neural stem cell model of sporadic congenital hydrocephalus (Photo courtesy of Yale University School of Medicine).
Image: A neural stem cell model of sporadic congenital hydrocephalus (Photo courtesy of Yale University School of Medicine).
Congenital hydrocephalus (CH), characterized by enlarged brain ventricles, is considered a disease of excessive cerebrospinal fluid (CSF) accumulation and thereby treated with neurosurgical CSF diversion with high morbidity and failure rates.

Congenital hydrocephalus is present in the infant prior to birth, meaning the fetus developed hydrocephalus in utero during fetal development. The most common cause of congenital hydrocephalus is aqueductal stenosis, which occurs when the narrow passage between the third and fourth ventricles in the brain is blocked or too narrow to allow sufficient CSF to drain.

A multidisciplinary team at Yale University School of Medicine (New Haven, CT, USA) performed whole-exome sequencing of 381 individuals with sporadic congenital hydrocephalus who were treated with neurosurgery, a cohort that included 232 parent-offspring trios. Another 1,798 trios of unaffected siblings and parents of individuals with autism spectrum disorder were analyzed in parallel as a control group.

The team uncovered 12 genes with two or more de novo mutations each that were predicted to be protein damaging. Five of these genes: TRIM71, SMARCC1, PTEN, PIK3CA, and FOXJ1, had significantly more mutations than expected. The investigators further estimated that about 22% of sporadic congenital hydrocephalus are due to rare, damaging mutations. The teams’ analysis additionally implicated a number of genes in the PI3K signaling pathway in congenital hydrocephalus. These genes regulate cell growth, proliferation, and differentiation in numerous tissues, including developing neural stem cells. In particular, they uncovered three de novo mutations in PI3KCA, three in PTEN, and two in MTOR.

Individuals with mutations in TRIM71, which maintains stem cell pluripotency, are more likely to have cranial nerve defect, non-obstructive inter-hemispheric cysts, and hearing loss. Meanwhile, individuals with mutations in SMARCC1, which regulates gene expression needed for neural stem cell proliferation, differentiation, and survival during telencephalon development, are more likely to have aqueductal stenosis and cardiac and skeletal abnormalities.

All together, the known, high-confidence, and probable risk genes for congenital hydrocephalus converge in gene co-expression networks of the mid-gestational human cortex, In particular, the congenital hydrocephalus risk genes converge on a network previously linked to autism spectrum disorder that is enriched for neuronal differentiation and RNA processing gene ontology terms.

Kristopher T. Kahle, MD, PhD, an assistant professor of neurosurgery and a senior author of the study, said, “It is possible that some of the neurological problems that many of these congenital hydrocephalus patients have may not be due to inadequately working shunts, but are in fact neurodevelopmental sequelae of a genetic condition that alters neuronal function.”

The authors concluded that that genetic disruptions affecting early brain development may drive sporadic congenital hydrocephalus. Their data implicate genetically encoded neural stem cell dysregulation and an associated impairment of fetal neurogliogenesis as primary pathophysiological events in a significant number of congenital hydrocephalus cases. The study was published on October 19, 2020 in the journal Nature Medicine.

Related Links:
Yale University School of Medicine

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Candida Glabrata Test
ELIchrom Glabrata

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL